# Full Framework Readiness Report — Phases 1, 2, 4, 5

Date: 2026-08-25
Scope: Complete generic, product-agnostic AI Agentic QA Automation Framework. No real
application was accessed, no real credentials were used, no product-specific business logic
was added, and no GitLab write operation occurred at any point.

---

# FINAL VERDICT

# READY FOR PHASE 3 PRODUCT ONBOARDING

---

## Architecture Status

The 12-agent architecture (Orchestrator + 11 specialists) defined in `ARCHITECTURE.md` remains
the sole orchestration model. **No duplicate agent, skill, orchestration engine, or skill-
discovery mechanism was created.** Every Phase 4/5 capability was implemented as either:
- a new, standalone module under `.framework/lib/` with no orchestration role of its own, or
- a small, additive, fully-tested extension to an existing agent/schema (documented per-item in
  `PHASE4_COMPLETION_REPORT.md` / `PHASE5_COMPLETION_REPORT.md` as either a "Part D deliberate
  extension" or the one "bug-fix exception"), or
- a validation pass with no new production code at all (A6's core properties, A12, B1, B3, B6's
  original capability).

## Capabilities Implemented (New)

Requirement change detection (A1), requirement impact analysis (A2), intelligent test selection
with explicit reasons (A3), risk scoring (A4), near-duplicate test detection (A8 extension),
test optimization recommendations (A9), quality gates (B7), release readiness (B8), named
environment configuration (B9), notification adapter interface (B11), configurable execution
profiles (B2), artifact retention policy (B5 extension), and a bug-fix restoring real retry
tracking (B4).

## Capabilities Already Existing and Reused

Self-healing's full safety model (confidence tiers, assertion guard, dry-run-only posture) —
Phase 1/2. Flaky-test detection core mechanism, gap analysis core mechanism, regression's dual
trigger paths and impact mapping, the full traceability manifest, the artifact store and schema
validator, the mock-server-based auth/API proof, CI config validation, and parallel-execution
safety — all Phase 1/2, reused without modification wherever Phase 4/5 needed their data.

## Capabilities Intentionally Deferred

- A9's `overlappingCoverage` and `lowValue` optimization recommendations — no real evidence
  source exists for either in this framework; fabricating them would violate "recommend only
  from actual evidence." Reported as `notComputed` with an explicit reason, not silently
  omitted.
- A4's `defectHistory` risk factor — no defect-tracking data source exists in this framework;
  always `null`.
- B14's "enterprise configuration" — documented as a review/table (see `PHASE5_COMPLETION_
  REPORT.md`) rather than built as a new aggregator module, since no real consumer for one
  exists yet.
- All real, product-specific requirement analysis, test design, automation, and business
  workflows — these belong to Phase 3 and were not started, per explicit instruction.

## Test Counts and Results

| Milestone | Total tests | Result |
|---|---|---|
| Start of this session (Phase 1 + Phase 2 baseline) | 95 | passing |
| First Phase 4 + Phase 5 pass | 239 | 239 passed, 0 failed |
| **This round — B7/B8/B11 real-evidence/wiring gap closure (final)** | **247** | **247 passed, 0 failed** |

152 new tests were added across 18 new spec files and 7 extended existing spec files, covering
every new/extended capability per Part F's required shape (happy path, empty/missing/malformed
input, boundary conditions, invalid configuration, concurrency where relevant, determinism, and
security-sensitive cases). The preserved original smoke test (`tests/home.spec.js`) still passes
unmodified, on all three browser projects.

Full command used for the final measurement: `npx playwright test` (all projects, `--workers=1`
to match the actual `playwright.config.js` CI setting — see Known Limitations). Result observed
directly, not estimated: **247 passed (1.4m)**.

This round closed two genuine gaps found during a self-critical re-review after the first
"READY" declaration: B7 (Quality Gates) and B8 (Release Readiness) had been built and tested
against hand-constructed evidence only, never against a real run's real artifacts; and B11
(notification adapter) had been built and tested in isolation, never actually invoked anywhere
in the pipeline. Both are now wired to real data and exercised end-to-end — see
`PHASE5_COMPLETION_REPORT.md` for full detail (`release-evidence.js`, and the `orchestrator.js`
Part D extension adding an optional `notifyAdapter` parameter to `runDryRunPipeline()`).

## Known Limitations

Listed in full in the Phase 4/5 reports; summarized:
- Two Phase 4 sub-recommendations (A9) are honestly left uncomputed for lack of real evidence.
- One Phase 4 risk factor (A4's defectHistory) is always unknown for the same reason.
- Requirement Analysis still only parses Markdown (a pre-existing, disclosed Phase 1 limitation,
  unchanged by this session).
- Logger secret redaction remains shallow (top-level keys only) — re-confirmed as not an active
  risk (audited every call site again this session; B10's new end-to-end test adds a second,
  independent layer of proof beyond the original unit test).
- **Unconstrained-parallel-worker flakiness (local-only, not a CI issue).** Running
  `npx playwright test` with Playwright's local default (auto-detected, multi-worker) parallelism
  occasionally fails 1-2 tests that each spin up their own real dry-run pipeline or mock-server
  session concurrently with several others (observed in `end-to-end-authentication.spec.js` and
  `ai-decision-auditability.spec.js`, a different test each run — consistent with worker resource
  contention, not a logic defect). `playwright.config.js` already sets `workers:
  process.env.CI ? 1 : undefined` — i.e. **CI itself always runs with a single worker**, and a
  full run under `--workers=1` (matching real CI behavior exactly) passes **247/247** with zero
  flakes, confirmed twice. This is a disclosed, pre-existing local-parallelism characteristic of
  the test suite, not introduced by this round's changes, and does not affect CI.

None of the above are blockers: each is a disclosed, evidence-based scoping decision, not a
broken or missing capability.

## Safety / Security Validation

- **GitLab remains read-only.** `.mcp.json` is byte-for-byte unchanged from before this session
  (diffed and confirmed). `.framework/lib/gitlab-adapter.js`'s five write functions
  (`createMergeRequest`, `mergeMergeRequest`, `pushToBranch`, `createIssue`, `postComment`)
  still unconditionally throw `GitLabWriteDisabledError`, re-verified by the existing
  `gitlab-write-disabled.spec.js` suite (unmodified, still passing).
- **Self-healing remains structurally safe.** The mechanical assertion-touch guard, the
  `pages/`-only write scope, and the schema-level `const false`/`const true` safety fields
  (`assertionTouched`, `dryRun`, `realFileWritePerformed`, `mrOpened`, `mergeApprovedByHuman`)
  are all unchanged. The one addition (`sourceFailureAnalysisId`) is a read-only traceability
  reference, not a new write capability.
- **Production execution remains blocked by default.** `environment-safety.js` is unchanged;
  the new `environment-config.js` (B9) routes every load through it and cannot bypass it
  (proven by test).
- **Secrets remain unexposed**, now proven at two levels: the original unit test on `redact()`,
  and this session's new end-to-end test that runs a real pipeline with a synthetic secret
  injected via environment variables and scans all resulting console output, artifacts, audit
  logs, and reports for it — zero matches.
- **No real application, URL, or credential was ever used or requested** during this session.

## CI Validation

`.gitlab-ci.yml` unchanged. Its existing validation suite (`ci-config-validation.spec.js`) still
passes, cross-checking stage order, script existence, and project existence against the real
`package.json`/`playwright.config.js`, and confirming the pipeline never references a GitLab-
write operation. New `npm run test:smoke`/`test:sanity`/`test:api`/`test:ui`/`test:changed`/
`artifact:prune` scripts were verified by live execution, not just by reading them.

## Artifact Validation

The original 200-artifact stress test (Phase 2) still passes unmodified. The new artifact-
retention module was tested against real run directories (creation, dry-run reporting, and
actual deletion when explicitly requested) without interacting with or weakening that stress
test's guarantees.

## Agent Validation

All 12 agents remain intact and were re-verified functional after every extension: standalone
CLI invocation (`node .framework/cli.js <agent>`), chained invocation, and the full orchestrated
dry-run pipeline all still complete successfully, and every existing test file that exercises an
extended agent was re-run and still passes unmodified.

## Product-Agnostic Validation

Every new capability operates on generic evidence types (artifacts, manifests, execution
history, config files) with no reference to any real product, business domain, or workflow. The
one demonstration dataset used throughout (the public `playwright.dev` "Get started"/search
scenario) is the same pre-approved, non-business demo established in Phase 0/1 — no new fictional
or real business domain was introduced at any point in Phases 4 or 5.

---

## Final Acceptance Checklist (Part H)

- [x] Phase 1 remains frozen (one disclosed bug-fix exception in `execution.js`, proven and documented; all else additive/untouched)
- [x] Phase 2 remains intact (all Phase 2 tests re-run, unmodified, still passing)
- [x] No real application was used
- [x] No product-specific business logic was added
- [x] All 12 existing agents remain intact
- [x] No duplicate agent architecture exists
- [x] UI foundation remains functional (smoke test passes on all 3 browsers)
- [x] API foundation remains functional (mock-server auth/API tests still pass)
- [x] Authentication foundation remains functional
- [x] Requirement analysis remains functional (+ change detection added)
- [x] Test design remains functional (+ near-duplicate detection added)
- [x] Test data remains functional
- [x] Automation generation remains functional
- [x] Execution remains functional (+ real retry tracking fixed)
- [x] Failure analysis remains functional (+ failure-group classification added)
- [x] Self-healing remains safe and auditable (+ source traceability added)
- [x] Flaky detection remains evidence-based (+ frequency/quarantine added)
- [x] Gap analysis remains functional (+ partial coverage added)
- [x] Regression remains functional (+ selection reasons added)
- [x] Reporting remains functional (+ failure diagnostics added)
- [x] Intelligent capabilities are validated (A1–A9, all tested)
- [x] Impact analysis is validated (A2)
- [x] Test selection is validated (A3)
- [x] Risk-based selection is validated (A4)
- [x] Traceability is validated (A11, end-to-end)
- [x] CI execution is validated (B1)
- [x] Parallel execution is validated (B3)
- [x] Retry behavior is validated (B4)
- [x] Artifact management is validated (B5)
- [x] Historical execution is validated (B6)
- [x] Quality gates are validated (B7)
- [x] Release readiness is validated (B8)
- [x] Environment configuration is validated (B9)
- [x] Secret safety is validated (B10, end-to-end)
- [x] CI diagnostics are validated (B12)
- [x] Documentation matches the actual implementation (this report + Phase 4/5 reports)
- [x] Full framework test suite passes — **247/247** (under `--workers=1`, matching real CI config)
- [x] Quality gates / release readiness evaluated against real run evidence, not just hand-built test fixtures (B7/B8)
- [x] Notification hook actually fires during a real pipeline run, and a delivery failure cannot fail the pipeline (B11)

All items satisfied. No genuine blockers were found.

---

## Stopping Point

Per instruction: development stops here. No Phase 3 work has been started — no real product was
onboarded, no real credentials were requested, no product-specific modules, test cases, or
Playwright/API scripts were created, and no business workflow was invented. The generic
framework baseline is complete and frozen as of this report.

**Waiting for real product/module information to begin Phase 3.**
